Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

4.5K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
4.5K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.1K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.1K
GPCR Desensitization01:12

GPCR Desensitization

8.3K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.3K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

17.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
17.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dibenzoylmethane, a novel β-diketone pore blocker of large-conductance calcium-activated potassium channel.

bioRxiv : the preprint server for biology·2026
Same author

Editorial: Linking the endocrine system with immunity.

Frontiers in endocrinology·2025
Same author

Non-canonical G<sub>q</sub> activation by orexin receptor type 2 and lemborexant observed in microsecond molecular dynamics simulations.

Scientific reports·2025
Same author

CacyBP/SIP - RPL6 interaction: potential influence on ribosome function.

Amino acids·2025
Same author

Cross-variant immune shield: computational multiepitope vaccine design against B.617.2 to Omicron sub-lineages in SARS-CoV-2.

Journal of biomolecular structure & dynamics·2025
Same author

GPCRVS - AI-driven Decision Support System for GPCR Virtual Screening.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Feb 17, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K

Approaches for Differentiation and Interconverting GPCR Agonists and Antagonists.

Przemysław Miszta1, Jakub Jakowiecki1, Ewelina Rutkowska1

  • 1Biological and Chemical Research Centre, Faculty of Chemistry, University of Warsaw, ul. Pasteura 1, 02-093, Warsaw, Poland.

Methods in Molecular Biology (Clifton, N.J.)
|December 1, 2017
PubMed
Summary

Predicting ligand functional effects on receptors is challenging. New methods leverage structural data and simulations to differentiate agonists and non-agonists for drug discovery.

Keywords:
ActivationAgonistsFingerprintsGPCRsLigand dockingMolecular dynamics

More Related Videos

Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.4K
Parallel Interrogation of &#946;-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

13.9K

Related Experiment Videos

Last Updated: Feb 17, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K
Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.4K
Parallel Interrogation of &#946;-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

13.9K

Area of Science:

  • Pharmacology and Structural Biology
  • Computational Chemistry

Background:

  • Distinguishing between receptor agonists, antagonists, and inverse agonists is difficult due to their binding site similarities.
  • Small structural ligand variations can significantly alter receptor activation states.

Purpose of the Study:

  • To explore advanced methods for predicting ligand functional preferences.
  • To differentiate between agonists and non-agonists for G protein-coupled receptors (GPCRs).

Main Methods:

  • Utilizing high-quality structural data from crystallized GPCR-ligand complexes.
  • Employing long-timescale molecular dynamics simulations to study receptor activation processes.
  • Integrating theoretical and experimental knowledge for method development.

Main Results:

  • Significant progress in obtaining detailed GPCR structural information.
  • Molecular dynamics simulations provide insights into GPCR activation mechanisms.
  • Development of sophisticated methods to discern agonist from non-agonist activity.

Conclusions:

  • Advanced structural and simulation techniques enhance understanding of GPCR-ligand interactions.
  • New methods facilitate the differentiation of agonists and non-agonists.
  • This facilitates the optimization of drug candidates targeting GPCRs.